9 results about "Tissue concentrations" patented technology

This invention provides a method for assessing the risk of hemorrhagic transformation based on a two-compartment model, comprising: acquiring CT perfusion image sequences related to the risk of hemorrhagic transformation; extracting arterial input functions and tissue concentration-time curves from the CT perfusion image sequences; extracting spatiotemporal features from the CT perfusion image sequences using a Transformer network; inputting the spatiotemporal features into a physical information neural network and processing them through a two-compartment model to obtain preliminary parameter estimates and parameter constraint terms; determining a joint loss function based on the preliminary parameter estimates and parameter constraint terms, and using the arterial input function and tissue concentration-time curves, wherein the joint loss function includes a data fitting loss term for fitting the observed data and a physical constraint loss term for constraining the physical consistency of the two-compartment model; and assessing the risk of hemorrhagic transformation based on the joint loss function. The parameters estimated by this invention have clear physical meaning and strictly conform to the physical model, making them easy for clinicians to understand and apply, and improving the reliability of the results.

The present application provides a kind of potassium channel regulator, its preparation method, pharmaceutical composition and application. Specifically provided are compounds as shown in formula V or pharmaceutically acceptable salts thereof. The potassium channel regulator compound of the present application has one or more of the following effect advantages: (1) novel structure; (2) good KCNQ2 / 3 channel opening activity; (3) weak KCNQ4, KCNQ5 opening activity, high KCNQ2 / 3 selectivity; (4) good in vivo efficacy, good protection effect on seizures; (5) low neuro-motor toxicity; (6) high brain-blood ratio; (7) high plasma, brain tissue concentration.

The invention discloses an application of MG53 in preparation of a medicine for treating alcoholic cardiomyopathy. By constructing an alcoholic cardiomyopathy model mouse, it is detected that the concentration of cardiac muscle tissue of the mouse is reduced, and it is proved that MG53 can be used as a potential marker for diagnosing alcoholic cardiomyopathy; the survival rate of mice and cardiac function indexes of cardiac ultrasonic detection can be effectively improved through intervention treatment of the MG53 recombinant protein, and it is proved that MG53 can be used as a potential medicine for treating the alcoholic cardiomyopathy and has important significance in prevention and treatment of the alcoholic cardiomyopathy. Meanwhile, it is verified that the MG53 can be applied to potential drugs for treating alcohol-related lipid metabolism disorders including the alcoholic cardiomyopathy and myocardial remodeling related diseases, and a new drug, health care product or food additive preparation and application scheme is provided for treatment of alcoholic cardiomyopathy and other alcohol-related damage.

The present invention provides a potassium channel modulator and a preparation method therefor, a pharmaceutical composition and a use. Specifically provided is a compound represented by formula V or a pharmaceutically acceptable salt thereof. The potassium channel modulator compound of the present invention has one or more of the following advantages: (1) a novel structure; (2) good KCNQ2 / 3 channel opening activity; (3) weak opening activity for KCNQ4 and KCNQ5 and high selectivity for KCNQ2 / 3; (4) good in vivo efficacy and effective protection against epileptic seizures; (5) low neuro-motor toxicity; (6) a high brain-to-blood ratio; and (7) high concentrations in plasma and brain tissue.

This invention provides a dosage regimen for the treatment of BK or JC polyomavirus infection in human subjects. [Solution] The administration regimen includes the steps of (a) parenterally administering a dose of an antibody or antigen-binding fragment that specifically binds to the VP1 protein of the polyomavirus to the subject; (b) measuring the serum or tissue concentration of the antibody or antigen-binding fragment in the subject; and (c) measuring the serum or tissue trough concentration (C trough The administration regimen includes the step of administering a further dose of the antibody or its antigen-binding fragment before the concentration drops to less than approximately 3-860 μg / mL, wherein the concentration of the antibody or its antigen-binding fragment in the serum or tissue during the treatment is reduced to the C trough Maintain a higher position.

A method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to which a therapeutic antibody has been administered is reported herein, wherein the interference of residual blood in a tissue sample from the experimental animal for determining the concentration of the therapeutic antibody in said tissue is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the formula: C tmAb,组织,det. = obtained by determining the concentration of the therapeutic antibody in a tissue sample of the experimental animal, C tmAb,血浆,det. = obtained by determining the concentration of the therapeutic antibody in a blood sample of the experimental animal directly before taking the tissue sample, C refmAb,组织,det. = obtained by determining the concentration of an inert reference antibody in a tissue sample of the experimental animal, C refmAb,血浆,det. = obtained by determining the concentration of an inert reference antibody in a blood sample of the experimental animal directly before taking the tissue sample, C 组织,样品 = obtained by determining the tissue concentration in the tissue sample, wherein the inert reference antibody does not penetrate into said tissue, wherein the inert reference antibody is administered 2 to 10 minutes before obtaining the tissue and blood samples.

A method of analyzing a biopsy sample containing tissue extracted from a prostate gland of a subject comprises measuring zinc level and an epithelial glandular tissue concentration in the sample, determining the likelihood that the sample is cancerous based on at least the zinc level and the epithelial glandular tissue concentration in the sample, and generating an output indicative of the likelihood.

The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.

The invention provides a regorafenib in-situ gel preparation for treating ocular neovascular diseases. The regorafenib in-situ gel preparation comprises regorafenib, a surfactant and an ion-sensitive in-situ gel material. According to the in-situ gel preparation disclosed by the invention, an in-situ gel preparation technology is combined with a particle drug carrier technology, and small molecules TKI are uniformly dispersed in an in-situ gel delivery carrier in the form of suspension particles by using suspension in-situ gel, or the small molecules TKI are encapsulated into nano-micelles and then dispersed in the in-situ gel delivery carrier, so that the in-situ gel preparation is prepared. The prepared particle in-situ gel ophthalmic preparation containing the micromolecule TKI is small in particle size, moderate in viscosity, stable in quality and free of irritation, and after the preparation is administrated in an eye drop mode, the eye tissue concentration and bioavailability of the preparation can be further remarkably improved, so that the intraocular curative effect of the preparation is improved.